Press release
Low-Grade Glioma Market is expected to reach USD 2.75 billion by 2034
Low-Grade Glioma
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70865
The LGG market is set for significant growth over the next decade, driven by advances in molecular profiling, the emergence of targeted therapies, improvements in neuroimaging, and increasing global access to specialized neuro-oncology care.
Market Overview
• Market Size (2024): USD 1.46 billion
• Forecasted Market Size (2034): USD 2.75 billion
• CAGR (2024-2034): ~6.5%
• Key Drivers: Integration of genetic testing in diagnosis, new targeted agents for specific mutations, and advancements in surgical techniques.
• Challenges: Long disease course requiring lifelong monitoring, limited curative options for recurrent LGG, and treatment side effects impacting cognitive function.
• Leading Players: F. Hoffmann-La Roche Ltd., Novartis AG, Bristol Myers Squibb, Merck & Co., Pfizer Inc., Amgen Inc., and Denovo Biopharma.
Segmentation Analysis
By Tumor Type
• Astrocytoma
• Oligodendroglioma
• Mixed Oligoastrocytoma
By Treatment Type
• Surgery
• Radiation Therapy
• Chemotherapy (Temozolomide, Procarbazine, Lomustine, Vincristine)
• Targeted Therapy (IDH inhibitors, BRAF inhibitors)
• Immunotherapy
By End Use
• Hospitals & Neurosurgery Centers
• Specialty Cancer Clinics
• Academic & Research Institutes
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Segmentation Summary
The standard approach to LGG involves maximal safe surgical resection, followed by tailored use of radiation and chemotherapy. Targeted therapies, particularly IDH inhibitors for IDH-mutant LGGs, are emerging as promising treatment options.
Explore Full Report here: https://exactitudeconsultancy.com/reports/70865/low-grade-glioma-market
Regional Analysis
North America
• Holds ~44% of market share in 2024.
• Strong adoption of molecular diagnostics and advanced surgical techniques.
• High availability of clinical trials for novel agents.
Europe
• Leading adoption of personalized treatment based on genetic markers.
• EMA approvals supporting targeted therapy use in LGG.
Asia-Pacific
• Fastest-growing region (CAGR > 8%).
• Improving access to neurosurgical facilities and advanced imaging in China, Japan, and India.
Middle East & Africa
• GCC countries investing in neuro-oncology centers.
• Limited specialized facilities in low-income areas.
Latin America
• Brazil and Mexico leading access to MRI-based diagnostics and surgery.
Regional Summary
While North America and Europe lead in technology adoption and research, Asia-Pacific is set for the highest growth, driven by healthcare modernization and expanded diagnostic capacity.
Market Dynamics
Key Growth Drivers
1. Molecular profiling integration in standard diagnosis and treatment planning.
2. Development of targeted therapies for IDH-mutant and BRAF-mutant LGGs.
3. Advancements in surgical navigation and intraoperative imaging.
4. Increasing participation in global clinical trials for LGG.
Key Challenges
1. Risk of malignant transformation over time.
2. Treatment side effects impacting neurocognitive outcomes.
3. Limited access to genetic testing in developing countries.
4. Long-term treatment costs due to extended disease management.
Latest Trends
• Increasing research into low-intensity treatment regimens to preserve cognitive function.
• Development of next-generation IDH inhibitors with improved BBB penetration.
• Use of AI-based imaging tools for better tumor segmentation and monitoring.
• Expansion of liquid biopsy research for non-invasive tumor tracking.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70865
Competitor Analysis
Major Players
• F. Hoffmann-La Roche Ltd. (Avastin® - supportive use in LGG management)
• Novartis AG
• Bristol Myers Squibb (Opdivo® - investigational trials in LGG)
• Merck & Co., Inc. (Keytruda® - PD-1 inhibitor research in LGG)
• Pfizer Inc.
• Amgen Inc.
• Denovo Biopharma
• Kintara Therapeutics, Inc.
• Celldex Therapeutics
• Blue Earth Diagnostics (advanced imaging solutions)
• GE Healthcare (neuroimaging equipment)
• Siemens Healthineers (AI-assisted MRI)
• Philips Healthcare (intraoperative imaging)
• Medtronic plc (neurosurgical devices)
Competitive Summary
The LGG market is technology-driven, with pharmaceutical companies focusing on targeted agents and medtech firms driving surgical and imaging innovation.
Conclusion
The low-grade glioma market is poised for steady growth as precision medicine, advanced imaging, and targeted therapy adoption become standard. By 2034, earlier diagnosis, better surgical outcomes, and personalized treatment will significantly improve patient quality of life.
Opportunities include:
• Expanding access to genetic testing globally.
• Developing therapies to delay malignant transformation.
• Integrating AI-powered imaging tools into routine care.
This report is also available in the following languages : Japanese (低悪性度神経膠腫市場), Korean (저등급 신경교종 시장), Chinese (低级别胶质瘤市场), French (Marché du gliome de bas grade), German (Markt für niedriggradige Gliome), and Italian (Mercato del glioma di basso grado), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/70865/low-grade-glioma-market#request-a-sample
Our More Reports:
Frontotemporal Dementia Market
https://exactitudeconsultancy.com/reports/70800/frontotemporal-dementia-market
Intoxication Market
https://exactitudeconsultancy.com/reports/70802/intoxication-market
Opioid Use Disorder Market
https://exactitudeconsultancy.com/reports/70804/opioid-use-disorder-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Low-Grade Glioma Market is expected to reach USD 2.75 billion by 2034 here
News-ID: 4144007 • Views: …
More Releases from Exactitude Consultancy
Malignant Pleural Mesothelioma Market is expected to reach USD 2.11 billion by 2 …
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural lining of the lungs, most often caused by prolonged asbestos exposure. It is associated with a poor prognosis due to late-stage diagnosis and limited curative options. Traditionally treated with surgery, chemotherapy, and radiation, the MPM market is undergoing transformation as immunotherapy, targeted agents, and advanced imaging gain traction.
Download Full PDF Sample Copy of Market Report…
Intrahepatic Cholangiocarcinoma Market is expected to reach USD 1.34 billion by …
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive form of bile duct cancer originating within the liver. It accounts for approximately 10-15% of primary liver cancers but has one of the poorest prognoses due to late-stage diagnosis and limited treatment options. Over recent years, genomic profiling has identified actionable mutations-including FGFR2 fusions, IDH1 mutations, and BRAF mutations-leading to the approval of targeted therapies and expanding treatment possibilities.
The iCCA market is…
High-Grade Glioma Market is expected to reach USD 9.92 billion by 2034
High-grade gliomas (HGGs) are aggressive brain tumors classified as WHO grade III (anaplastic astrocytoma, anaplastic oligodendroglioma) and grade IV (glioblastoma multiforme). They represent some of the most challenging cancers to treat due to their rapid growth, infiltrative nature, and high recurrence rates. Standard-of-care typically involves surgery, radiation, and chemotherapy, but median survival remains limited, especially for glioblastoma patients.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70861
The next decade will…
Hairy Cell Leukemia Market is expected to reach $1.18 billion by 2034
Hairy cell leukemia (HCL) is a rare, slow-growing type of chronic B-cell leukemia characterized by the abnormal growth of B lymphocytes. The disease is named for the hair-like projections seen on the surface of cancer cells under a microscope. Despite being rare, HCL is one of the most treatable leukemias, with long remission periods achievable through targeted chemotherapy and immunotherapy.
Over the next decade, the HCL market will benefit from innovations…
More Releases for LGG
Low-Grade Glioma Market Forecast 2025-2034: Analysing Major Trends, Opportunitie …
What industry-specific factors are fueling the growth of the low-grade glioma market?
The growing incidence of brain tumors is expected to drive the expansion of the low-grade glioma market in the near future. A brain tumor refers to an abnormal cell growth within the brain or nearby regions, which can be benign or malignant. The rise in brain tumor cases is linked to factors such as increased radiation exposure, environmental pollutants,…
Low Grade Glioma Market to Register Incremental Growth During the Forecast Perio …
DelveInsight's "Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Low Grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Low Grade Glioma…
Low Grade Glioma Market to Register Incremental Growth During the Forecast Perio …
The Low Grade Glioma Market size was valued approximately USD 1 billion in 2022 and the report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the 7MM.
DelveInsight's "Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low…
The Scale of the Edible Lactobacillus Rhamnosus GG(LGG) Market: A Deep Dive
In this report, analysts conduct a comprehensive study of the global Edible Lactobacillus Rhamnosus GG(LGG) market, examining essential factors including drivers, challenges, recent trends, opportunities, advancements, and the competitive landscape. The report aims to provide a clear understanding of both current and future scenarios within the global Edible Lactobacillus Rhamnosus GG(LGG) industry. Researchers employ research methodologies like PESTLE and Porter's Five Forces analysis to assess the market. Accurate data on…
Edible Lactobacillus Rhamnosus GG(LGG) Market Size, Analytical Overview, Growth …
Los Angeles, United State: The global Edible Lactobacillus Rhamnosus GG(LGG) market is comprehensive and accurately presented in the report with the help of detailed market information and data, critical findings, error-free statistics, and reliable forecasts. The report digs deep into important aspects of the global Edible Lactobacillus Rhamnosus GG(LGG) market, including competition, segmentation, regional expansion, and market dynamics. Each leading trend of the global Edible Lactobacillus Rhamnosus GG(LGG) market is…
Probiotic Yogurt Market Astonishing Growth by 2024| Danone, General Mills, Nestl …
HTF MI recently introduced Global Probiotic Yogurt Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Danone, General Mills, Nestle, Valio, Danisco, Lifeway Foods Incorporation, Morinaga Milk…
